CY1124768T1 - Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις - Google Patents
Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενειςInfo
- Publication number
- CY1124768T1 CY1124768T1 CY20211100629T CY211100629T CY1124768T1 CY 1124768 T1 CY1124768 T1 CY 1124768T1 CY 20211100629 T CY20211100629 T CY 20211100629T CY 211100629 T CY211100629 T CY 211100629T CY 1124768 T1 CY1124768 T1 CY 1124768T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibody
- level
- treatment
- biomarker
- therapy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 3
- 239000000090 biomarker Substances 0.000 abstract 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 210000000822 natural killer cell Anatomy 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα αποκάλυψη απευθύνεται σε μία μέθοδο ταυτοποίησης ενός ατόμου που έχει χρόνια λεμφοκυτταρική λευχαιμία (CLL), μη-Hodgkin λέμφωμα (NHL), μικρό λεμφοκυτταρικό λέμφωμα (SLL) ή οξεία λεμφοβλαστική λευχαιμία (ALL) που αποκρίνεται στη θεραπεία με ένα αντίσωμα αντι-CD19, με την εν λόγω μέθοδο να περιλαμβάνει: α) παροχή δείγματος αίματος που ελήφθη από το εν λόγω άτομο πριν από τη θεραπεία με το εν λόγω αντίσωμα αντι-CD19, β) προσδιορισμό του επιπέδου τουλάχιστον ενός βιοδείκτη στο εν λόγω δείγμα που επιλέγεται από την ομάδα που αποτελείται από: i) αριθμό περιφερικών ΝΚ κυττάρων και ii) επίπεδα έκφρασης CD16 σε περιφερικά κύτταρα ΝΚ, γ) σύγκριση του επιπέδου του εν λόγω τουλάχιστον ενός βιοδείκτη στο εν λόγω δείγμα με ένα προκαθορισμένο επίπεδο αποκοπής, όπου τα επίπεδα του εν λόγω τουλάχιστον ενός βιοδείκτη σε ή πάνω από το προκαθορισμένο επίπεδο αποκοπής είναι ενδεικτικά ενός ατόμου που θα επωφεληθεί από τη θεραπεία με ένα αντι-CD19 αντίσωμα. Η παρούσα αποκάλυψη απευθύνεται επίσης σε μία μέθοδο επιλογής ενός ασθενούς για θεραπεία σύμφωνα με τα παραπάνω και για την χρήση ενός αντι-CD19 αντισώματος για την θεραπεία ενός τέτοιου ασθενούς.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124768T1 true CY1124768T1 (el) | 2022-11-25 |
Family
ID=56116221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100629T CY1124768T1 (el) | 2016-05-30 | 2021-07-13 | Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (el) |
| EP (2) | EP3465214B1 (el) |
| JP (2) | JP7066639B2 (el) |
| KR (1) | KR102416144B1 (el) |
| CN (2) | CN109313194B (el) |
| AU (1) | AU2017272608B2 (el) |
| BR (1) | BR112018074603A2 (el) |
| CA (1) | CA3025823A1 (el) |
| CY (1) | CY1124768T1 (el) |
| DK (2) | DK3916392T3 (el) |
| EA (1) | EA201892542A1 (el) |
| ES (1) | ES2878156T3 (el) |
| HR (1) | HRP20210938T1 (el) |
| HU (1) | HUE054860T2 (el) |
| IL (1) | IL263103B2 (el) |
| LT (1) | LT3465214T (el) |
| MA (1) | MA45124B1 (el) |
| MD (1) | MD3465214T2 (el) |
| MX (2) | MX2018014702A (el) |
| PL (1) | PL3465214T3 (el) |
| PT (1) | PT3465214T (el) |
| RS (1) | RS62155B1 (el) |
| SG (2) | SG11201810159TA (el) |
| SI (1) | SI3465214T1 (el) |
| WO (1) | WO2017207574A1 (el) |
| ZA (1) | ZA201808647B (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021013101A (es) * | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| WO2021084064A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
| BR112022017162A2 (pt) * | 2019-10-31 | 2022-10-18 | Morphosys Ag | Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma |
| KR20230131464A (ko) * | 2020-12-04 | 2023-09-13 | 모르포시스 아게 | 항-cd19 병용 요법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112084B2 (en) * | 1998-08-11 | 2012-04-25 | Biogen Idec Inc. | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| CA2439410C (en) | 2001-02-27 | 2011-09-06 | William D. Figg | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
| EA200800094A1 (ru) | 2005-06-20 | 2008-06-30 | Медарекс, Инк. | Антитела cd19 и их использование |
| KR101397290B1 (ko) | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-ｃｄ19 항체 |
| SI2059536T1 (sl) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimirana protitelesa, ki ciljajo CD19 |
| PT2066349E (pt) | 2006-09-08 | 2012-07-02 | Medimmune Llc | Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes |
| DE602007013068D1 (de) * | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| KR20110122859A (ko) | 2009-02-23 | 2011-11-11 | 그렌마크 파머수티칼스 에스. 아. | Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| WO2012067981A1 (en) * | 2010-11-15 | 2012-05-24 | Medimmune, Llc | Combination therapy for b cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP4083071A3 (en) * | 2011-08-16 | 2023-02-22 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a purine analog |
| ES2909722T3 (es) * | 2011-08-16 | 2022-05-10 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada |
| CA2858906A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
| CN106029098A (zh) * | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
| JP2017519757A (ja) * | 2014-06-16 | 2017-07-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | 慢性リンパ球性白血病（ｃｌｌ）の処置 |
| WO2016005548A1 (en) * | 2014-07-11 | 2016-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active IP Right Grant
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 MX MX2018014702A patent/MX2018014702A/es unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 CA CA3025823A patent/CA3025823A1/en active Pending
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-06-11 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP2022119764A/ja active Pending
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124768T1 (el) | Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| BR112018074406A2 (pt) | métodos para o tratamento de malignidades de células b utilizando terapia celular adotiva | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
| WO2015110923A3 (en) | Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia | |
| Millot et al. | Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase | |
| EA201792545A1 (ru) | Способы и наборы для лечения депрессии | |
| Toulany et al. | ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition | |
| MX2017005751A (es) | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. | |
| SI2925888T1 (en) | Compounds and methods for the treatment of cancer | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| BR112019022488A2 (pt) | Biomarcadores para terapêutica do câncer | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| CY1125071T1 (el) | Θεραπεια του συνδρομου ευθραυστου χ με κανναβιδιολη | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| BR112018074152A8 (pt) | Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico | |
| TR201909951T4 (tr) | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. | |
| MX2016013910A (es) | Tratamiento del cancer. | |
| Sasse et al. | Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group | |
| CY1124881T1 (el) | Στρωματωση γονοτυπου στην θεραπεια και προληψη του διαβητη | |
| AR104805A1 (es) | Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet | |
| BR112022010310A2 (pt) | Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b | |
| Beheshti et al. | Age and space irradiation modulate tumor progression: implications for carcinogenesis risk |